Join
Live feed
·
PRReleasevia Quantisnow
Sarepta Therapeutics Inc. logo

Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy

ByQuantisnow·Wall Street's wire, on your screen.
SRPT· Sarepta Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SRPT (Sarepta Therapeutics Inc.) and more on Quantisnow.